UniSa - IRIS Institutional Research Information System

PAPACCIO, Federica
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 4.186
NA - Nord America 1.509
EU - Europa 889
SA - Sud America 248
Continente sconosciuto - Info sul continente non disponibili 160
AF - Africa 30
OC - Oceania 5
Totale 7.027
Salva come PNG Salva come JPEG
Nazione #
HK - Hong Kong 3.135
US - Stati Uniti d'America 1.449
IT - Italia 511
SG - Singapore 505
BR - Brasile 184
CN - Cina 133
RU - Federazione Russa 130
VN - Vietnam 127
BD - Bangladesh 104
FR - Francia 64
KR - Corea 53
DE - Germania 41
IE - Irlanda 31
CA - Canada 28
GB - Regno Unito 27
IN - India 26
AR - Argentina 24
NL - Olanda 24
MX - Messico 16
IQ - Iraq 15
JP - Giappone 14
TR - Turchia 13
UA - Ucraina 12
CO - Colombia 10
AT - Austria 9
ID - Indonesia 9
ES - Italia 8
UZ - Uzbekistan 8
VE - Venezuela 8
ZA - Sudafrica 7
BE - Belgio 6
PK - Pakistan 6
EC - Ecuador 5
FI - Finlandia 5
KE - Kenya 5
PL - Polonia 5
BO - Bolivia 4
DZ - Algeria 4
GE - Georgia 4
JO - Giordania 4
MA - Marocco 4
MY - Malesia 4
PH - Filippine 4
RO - Romania 4
AU - Australia 3
AZ - Azerbaigian 3
CL - Cile 3
CR - Costa Rica 3
NP - Nepal 3
PE - Perù 3
UY - Uruguay 3
BH - Bahrain 2
CZ - Repubblica Ceca 2
EE - Estonia 2
EG - Egitto 2
HU - Ungheria 2
JM - Giamaica 2
LK - Sri Lanka 2
PA - Panama 2
PY - Paraguay 2
SA - Arabia Saudita 2
SE - Svezia 2
TH - Thailandia 2
TT - Trinidad e Tobago 2
TW - Taiwan 2
AM - Armenia 1
AO - Angola 1
BW - Botswana 1
CI - Costa d'Avorio 1
CW - ???statistics.table.value.countryCode.CW??? 1
DK - Danimarca 1
DO - Repubblica Dominicana 1
ET - Etiopia 1
GA - Gabon 1
GP - Guadalupe 1
GT - Guatemala 1
GY - Guiana 1
HN - Honduras 1
IL - Israele 1
KH - Cambogia 1
KI - Kiribati 1
KZ - Kazakistan 1
LB - Libano 1
ML - Mali 1
MQ - Martinica 1
MR - Mauritania 1
NA - Namibia 1
NI - Nicaragua 1
NO - Norvegia 1
NZ - Nuova Zelanda 1
OM - Oman 1
PT - Portogallo 1
RS - Serbia 1
SR - Suriname 1
SV - El Salvador 1
Totale 6.868
Salva come PNG Salva come JPEG
Città #
Hong Kong 3.134
San Jose 265
Milan 246
Singapore 243
Dallas 143
Ashburn 138
Chandler 128
Princeton 95
Council Bluffs 82
Rome 63
Lauterbourg 61
Moscow 54
Ho Chi Minh City 47
The Dalles 47
Hanoi 30
Dublin 29
Santa Clara 29
Beijing 25
Los Angeles 25
Andover 24
Figino 24
New York 23
Redwood City 23
Naples 21
Wilmington 18
Amsterdam 15
Ann Arbor 15
Tokyo 14
Frankfurt am Main 13
São Paulo 13
Turin 13
Buffalo 11
Nuremberg 11
Seattle 11
Chicago 10
Da Nang 10
Phoenix 9
San Francisco 9
Toronto 9
Seoul 8
Tashkent 8
Washington 8
Baghdad 7
Curitiba 7
Dhaka 7
Montreal 7
Charlotte 6
Istanbul 6
Johannesburg 6
Sarno 6
Vienna 6
Brooklyn 5
Caracas 5
Medellín 5
Mexico City 5
Munich 5
Taranto 5
Amman 4
Atlanta 4
Boston 4
Brasília 4
Campinas 4
Houston 4
Jacksonville 4
Memphis 4
New Delhi 4
Orem 4
Poggiomarino 4
Springfield 4
Warsaw 4
Aprilia 3
Baku 3
Belo Horizonte 3
Chennai 3
Cochabamba 3
Columbus 3
Duncan 3
Edinburgh 3
Genoa 3
González Catán 3
Haiphong 3
Hangzhou 3
Kuala Lumpur 3
London 3
Mar del Plata 3
Miami 3
Mumbai 3
Nairobi 3
Nha Trang 3
Norwalk 3
Nova Iguaçu 3
Paris 3
Porto Alegre 3
Pune 3
Rio de Janeiro 3
Salerno 3
San José 3
Tbilisi 3
Altofonte 2
Assago 2
Totale 5.432
Salva come PNG Salva come JPEG
Nome #
Mitochondrial transfer from Adipose stem cells to breast cancer cells drives multi-drug resistance 876
Metformin increases antitumor activity of MEK inhibitors through GLI1 downregulation in LKB1 positive human NSCLC cancer cells 720
Adipose Stem Cells and Their Interplay with Cancer Cells and Mitochondrial Reservoir: A New Promising Target 485
null 417
DNA-PK inhibition sustains the antitumor innate immune response in small cell lung cancer 345
Pulmonary Large-Cell Neuroendocrine Carcinoma: From Epidemiology to Therapy 286
Combined Therapeutic Strategies Based on the Inhibition of Non-Oncogene Addiction to Improve Tumor Response in EGFR- and KRAS-Mutant Non-Small-Cell Lung Cancer 218
Anti-PD1 therapy effects on T cell repertoire and functions in patients with NSCLC cancer: a preliminary study to identify biomarkers of efficacy 139
Role of the Hedgehog pathway in preventing occurrence of resistance to first, second, third generation EGFR-TKIs in first line therapy of NSCLC models with EGFR activating mutations 134
A multicenter, open-label phase II study of metformin with erlotinib in second-line therapy of stage IV non-small-cell lung cancer patients: treatment rationale and protocol dynamics of the METAL trial 126
Decoding chromosomal instability insights in CRC by integrating omics and patient-derived organoids 112
Detection of postoperative plasma circulating tumour DNA and lack of CDX2 expression as markers of recurrence in patients with localised colon cancer 97
Implication of the Hedgehog pathway in hepatocellular carcinoma 93
"Proteotranscriptomic analysis of advanced colorectal cancer patient derived organoids for drug sensitivity prediction" 89
Concise Review: Cancer Cells, Cancer Stem Cells, and Mesenchymal Stem Cells: Influence in Cancer Development 83
A new inhibitor of glucose-6-phosphate dehydrogenase blocks pentose phosphate pathway and suppresses malignant proliferation and metastasis in vivo 76
Glucose-6-phosphate dehydrogenase blockade potentiates tyrosine kinase inhibitor effect on breast cancer cells through autophagy perturbation 76
Precision Medicine to Treat Advanced Gastroesophageal Adenocarcinoma: A Work in Progress 75
HDAC2 depletion promotes osteosarcoma's stemness both in vitro and in vivo: a study on a putative new target for CSCs directed therapy 75
PBMCs as Tool for Identification of Novel Immunotherapy Biomarkers in Lung Cancer 73
Ex vivo lung cancer spheroids resemble treatment response of a patient with NSCLC to chemotherapy and immunotherapy: Case report and translational study 73
HGF/MET and the Immune System: Relevance for Cancer Immunotherapy 72
MiR-423-5p prevents MALAT1-mediated proliferation and metastasis in prostate cancer 71
Efficacy of osimertinib in combination with Hedgehog pathway inhibitors in reverting T790M-mediated resistence 70
Human primary bone sarcomas contain CD133+ cancer stem cells displaying high tumorigenicity in vivo 68
Cancer stem cells in solid tumors: an overview and new approaches for their isolation and characterization 68
Molecular profiling of advanced solid tumours. The impact of experimental molecular-matched therapies on cancer patient outcomes in early-phase trials: the MAST study 68
Results of the safety run-in part of the METAL (METformin in Advanced Lung cancer) study: a multicentre, open-label phase I-II study of metformin with erlotinib in second-line therapy of patients with stage IV non-small-cell lung cancer 65
Increased fucosylation has a pivotal role in invasive and metastatic properties of head and neck cancer stem cells 65
Pharmacological targeting of the ephrin receptor kinase signalling by GLPG1790 in vitro and in vivo reverts oncophenotype, induces myogenic differentiation and radiosensitizes embryonal rhabdomyosarcoma cells 65
Neoadjuvant Chemotherapy in Locally Advanced Rectal Cancer 63
Prognostic Nutritional Index as an independent prognostic factor in locoregionally advanced squamous cell head and neck cancer 62
In the literature: August 2018 62
Circulating cancer stem cells: an interesting niche to explore 61
NK cell receptors in anti-tumor and healthy tissue protection: Mechanisms and therapeutic advances 61
Insulitis in Human Type 1 Diabetic Pancreas: From Stem Cell Grafting to Islet Organoids for a Successful Cell-Based Therapy 59
SMO Gene Amplification and Activation of the Hedgehog Pathway as Novel Mechanisms of Resistance to Anti-Epidermal Growth Factor Receptor Drugs in Human Lung Cancer 59
Novel applications of liquid Biopsy: Comprehensive methodology for circulating biomarker exploration in peripheral blood 55
ITGB1 and DDR activation as novel mediators in acquired resistance to osimertinib and MEK inhibitors in EGFR-mutant NSCLC 54
Stemness markers of osteosarcoma 54
ZNF518B as a transcriptional factor involved in colorectal cancer progression through the epithelial to mesenchymal transition 53
Efficacy of second and third generation EGFR tyrosine kinase inhibitors, alone or in combination, in T790M-mediated resistance 51
How organoids can improve personalized treatment in patients with gastro-esophageal tumors 51
Development of a living organoid biobank derived from colorectal cancer patients: Towards personalized medicine 51
Patient-derived organoids as a tool for modelling localized colorectal cancer 50
Urtica dioica L. inhibits proliferation and enhances cisplatin cytotoxicity in NSCLC cells via Endoplasmic Reticulum-stress mediated apoptosis 50
Effect of MEK inhibition on PDL1 and and on cytokinesproduction profilein NSCLC cell lines and in human lymphocites 49
CNAs concordance between CRC-PDOs and the original tissue reveals relevant oncogenic pathways alterations 49
Mutation tracking in circulating tumour DNA (ctDNA) detects minimal residual disease (MRD) in patients with localized colorectal cancer (CRC) and identifies those at high risk of recurrence regardless of stage, lack of CDX2 expression and CMS subtype 48
Effect of MEK inhibition on PD-L1 and MCH-1 expression and on cytokines production profile in NSCLC cells and in human lymphocites 47
Synergistic effects of oncogene inhibition and pyruvate dehydrogenase kinase blockade in resistant NSCLC cells 45
A novel ImmunoScore, based on clinical and blood biomarkers, as prognostic model for immunotherapy in NSCLC 45
The landscape of combining immune checkpoint inhibitors with novel Therapies: Secret alliances against breast cancer 44
Prognostic nutritional index (PNI) is an independent prognostic factor in locoregionally advanced squamous cell head and neck cancer (LAHNSCC) 44
Metastatic colorectal cancer derived organoids recapitulate genomic profile and treatment response of the original tumor 44
3D patient-derived gastric cancer organoids as a tool for functional precision medicine for gastric cancer patients 44
An integrated analysis of gene expression profile and chromosomal aberrations highlighted the oxidative stress role in anti-HER2 drug-resistant gastric cancer models 43
Anti-PD1 therapy effects on T cell repertoire and functions in patients with NSLC cancer: a preliminary study to identify biomarkers of efficacy 41
Role of HGF-MET Signaling in Primary and Acquired Resistance to Targeted Therapies in Cancer. 40
Will Organoids Fill the Gap towards Functional Precision Medicine? 37
Efficacy of sequential treatment with first, second and third generation EGFR inhibitors and role of Hedgehog pathway in the acquisition of resistance in in vivo NSCLC models 37
New insights from KISS activity: a prognostic biomarker in malignant pleural mesothelioma 36
Antitumoral efficacy of dual blockade of EGFR signaling by osimertinib in combination with selumetinib or cetuximab in activated EGFR human NSCLC tumor models 34
Met/Axl system as a dual target in the mesothelioma pathway and invasiveness 33
Results of safety run-in part in Metal (METformin in Advanced Lung cancer) trial 31
Reversion of mesenchymal behaviour by AZD9291 (osimertinib) in EGFR mutant NSCLC cell lines resistant to first generation EGFR tyrosine kinase inhibitors 31
Synergistic effect of vismodegib and cisplatin in NSCLC models via autophagy 28
The role of chemotherapy in localized and locally advanced rectal cancer: A systematic revision 1
Totale 7.027
Salva come PNG Salva come JPEG
Categoria #
all - tutte 21.430
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 21.430
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022124 0 0 2 0 1 0 0 10 26 0 16 69
2022/2023370 26 0 6 42 46 72 6 52 83 2 30 5
2023/2024202 7 14 10 4 10 34 4 8 28 2 9 72
2024/2025630 8 24 37 17 27 76 107 34 95 40 72 93
2025/20265.324 841 1.388 1.215 79 257 94 481 104 132 247 97 389
2026/2027281 216 65 0 0 0 0 0 0 0 0 0 0
Totale 7.027